Sodium Colistimethate I: Dissociations of Aminomethanesulfonates in Aqueous Solution

McMillan, Freeman H.; Pattison, I.

doi:10.1002/jps.2600580618

Cited by 19 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, using high-performance liquid chromatography (HPLC) our group demonstrated the presence of colistin and various unidentified degradation products arising from the storage of colistin methanesulphonate in aqueous solutions [64]. McMillan and Pattison employed nuclear magnetic resonance, infrared and electrophoresis to show that the hydrolysis of the methanesulphonate group in a simple model compound, nbutylaminomethane-sulphonic acid involved a series of complex equilibria [69]. Unfortunately, the additional complexity introduced by the presence of five sulphomethyl groups per molecule, limited a full investigation of hydrolysis kinetics of colistin methanesulphonate.…”

Section: Chemistrymentioning

confidence: 99%

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

Nation

Milne

et al. 2005

International Journal of Antimicrobial Agents

493

442

View full text Add to dashboard Cite

Section: Chemistrymentioning

confidence: 99%

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

Nation

Milne

et al. 2005

International Journal of Antimicrobial Agents

493

442

View full text Add to dashboard Cite

“…Colistimethate sodium is a nonactive prodrug, and after parenteral administration, colistin is formed in vitro and in vivo (18,19). In aqueous solutions, the colistimethate sodium is hydrolyzed and forms a complex mixture of partially sulfomethylated derivatives and colistin (22). Under different conditions, different proportions of colistimethate sodium are hydrolyzed to colistin.…”

mentioning

confidence: 99%

Colistin: The phoenix Arises

Conly

Johnston

2006

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

The polymyxins were discovered in the 1940s and represent a group of closely related polypeptide antibiotics obtained fromBacillus polymyxa, which was originally isolated from soil (1,2). Although they have been used extensively worldwide in topical otic and ophthalmic solutions for decades, the intravenous formulations were gradually abandoned in most parts of the world in the early 1980s because of the reported high incidence of nephrotoxicity (3-5). As a result, the use of polymyxin preparations has been mainly restricted to the treatment of lung infections due to multidrug-resistant (MDR) gram-negative bacteria in patients with cystic fibrosis (6,7). The emergence of bacteria resistant to most classes of commercially available antibiotics and the shortage of novel antimicrobial agents with activity against gram-negative microorganisms have led to the reemergence of polymyxins as a valuable addition to the therapeutic armamentarium. It was thus considered timely to review colistin and its emerging role in managing infections due to MDR gram-negative bacteria.

show abstract

“…Colistimethate sodium is hydrolyzed to form various partially sulfomethylated derivatives and colistin sulfate. 109 However, the proportion of colistimethate sodium hydrolyzed to colistin varies with time and temperature. 109,110 The majority of clinical studies involving polymyxin dosing strategies and outcomes were conducted before the development of modern pharmacodynamic concepts.…”

Section: Polymyxinsmentioning

confidence: 99%

“…109 However, the proportion of colistimethate sodium hydrolyzed to colistin varies with time and temperature. 109,110 The majority of clinical studies involving polymyxin dosing strategies and outcomes were conducted before the development of modern pharmacodynamic concepts. Also, most available studies do not differentiate between colistin sulfate and colistimethate sodium, and the range of patient populations studied has been relatively narrow, with the majority of patients studied having cystic fibrosis.…”

Section: Polymyxinsmentioning

confidence: 99%